Physician profile
Michael A Baird
NPI 1346252459
$3,668.70
in general payments reported to CMS, 2019-2025
20 companies · $21.47 in 2025
The $21.47 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $1,560 · 2023: $1,634 · 2024: $98.89 · 2025: $21.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668 · Education: $86.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.54 |
| Education | $86.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $745.90 | 2021-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $740.87 | 2021-2023 | Stelara, Remicade, Simponi Aria |
| Abbvie INC. | $485.33 | 2021-2024 | Linzess, Viberzi, Creon |
| Ironwood Pharmaceuticals, INC | $381.17 | 2021-2024 | Linzess |
| Genzyme Corporation | $236.33 | 2022-2023 | |
| Ardelyx, INC. | $204.20 | 2022-2023 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $190.27 | 2022-2023 | Dupixent |
| Qol Medical, LLC | $173.45 | 2022 | |
| Redhill Biopharma INC. | $167.67 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Nestle Healthcare Nutrition INC. | $107.87 | 2021-2023 | |
| Evoke Pharma, INC. | $56.26 | 2022-2023 | Gimoti |
| Merck Sharp & Dohme LLC | $45.17 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.49 | 2021-2024 | Entyvio |
| Pfizer INC. | $18.75 | 2024 | |
| Lucid Diagnostics INC. | $18.50 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $15.97 | 2023 | |
| Electromed, INC. | $13.88 | 2025 | Smartvest |
| Braintree Laboratories, INC. | $13.39 | 2023 | Suflave |
| Gilead Sciences, INC. | $12.64 | 2022 | |
| Phathom Pharmaceuticals, INC. | $7.59 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.